The aim of this study was to evaluate the plasma levels of prothrombotic markers--von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA)--in asymptomatic subjects with dyslipidemia. Asymptomatic subjects with dyslipidemia and their relatives (n = 234) were assessed for lipids and prothrombotic markers. Individuals were divided into four dyslipidemic phenotypes (DLP) according to apolipoprotein B (apoB) and triglycerides (TG): DLP1 (n = 58, apoB < 1.2 g/l and TG < 1.5 mmol/l), DLP2 (n = 47, apoB < 1.2 g/l and TG ≥ 1.5 mmol/l), DLP3 (n = 31, apoB ≥ 1.2 g/l and TG < 1.5 mmol/l) and DLP4 (n = 98, apoB ≥ 1.2 g/l and TG ≥ 1.5 mmol/l). Associations between prothrombotic markers and risk factors for atherosclerosis, markers of insulin resistance, and the intima-media thickness of the common carotid artery (IMT) were assessed too. Significant differences in PAI-1 between normolipidemic phenotype--DLP1 (62.5 (35.9-82.9) ng/ml) and hypertriglyceridemic phenotypes--DLP2 (82.2 (61.1-122.1) ng/ml, p < 0.01) and DLP4 (91.4 (63.5-111.8) ng/ml, p < 0.001) after adjustment for age, sex and body mass index, were found. Levels of t-PA were different only between DLP1 and DLP4 (1.9 (0.9-3.3) ng/ml vs. 5.3 (2.5-8.6) ng/ml, p < 0.05). There were no significant differences of vWF between DLPs. PAI-1 and t-PA correlated with lipid parameters, markers of insulin resistance, blood pressure and obesity. VWF was independently associated with IMT, which was increased in DLP4. Individuals with hypertriglyceridemic phenotypes showed increased levels of PAI-1 in comparison with normolipidemic subjects. The elevation of t-PA was presented only in patients with simultaneously elevated TG and apoB. The significant increase of IMT confirmed in the patients with DLP4 reveals individuals with the highest risk for atherosclerosis manifestation.

3rd Department of Internal Medicine University Hospital IP Pavlova 6 77520 Olomouc Czech Republic

See more in PubMed

Clin Sci (Lond). 1990 Nov;79(5):513-6 PubMed

Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1716-22 PubMed

Angiology. 1996 Jan;47(1):61-6 PubMed

Clin Chem. 1997 Dec;43(12):2364-78 PubMed

Diabetes. 2006 Feb;55(2):530-7 PubMed

Am J Nephrol. 2004 Jan-Feb;24(1):154-61 PubMed

Clin Biochem. 2009 Aug;42(12):1246-51 PubMed

Arterioscler Thromb. 1992 Jan;12(1):19-27 PubMed

Diabetes. 2006 Apr;55(4):1133-40 PubMed

Am J Cardiol. 1995 Jun 15;75(17):1189-95 PubMed

Can J Cardiol. 1999 Apr;15(4):409-18 PubMed

J Intern Med. 2002 Aug;252(2):155-63 PubMed

Thromb Haemost. 2000 Apr;83(4):545-8 PubMed

Arterioscler Thromb Vasc Biol. 1996 Feb;16(2):310-6 PubMed

Blood. 1990 Sep 1;76(5):930-7 PubMed

Vasc Med. 2004 Feb;9(1):46-54 PubMed

Clin Rheumatol. 2007 Apr;26(4):533-7 PubMed

Eur Heart J. 1994 Jun;15(6):781-5 PubMed

Circulation. 2008 Dec 9;118(24):2533-9 PubMed

Can J Cardiol. 2007 Oct;23 Suppl B:23B-31B PubMed

J Clin Epidemiol. 1997 Jul;50(7):801-7 PubMed

Prog Cardiovasc Dis. 1992 Mar-Apr;34(5):309-16 PubMed

Scand J Clin Lab Invest. 1998 Oct;58(6):475-83 PubMed

N Engl J Med. 1995 Mar 9;332(10):635-41 PubMed

Am J Cardiol. 2000 Aug 15;86(4):412-6 PubMed

Int J Obes Relat Metab Disord. 1998 Apr;22(4):312-7 PubMed

Thromb Haemost. 1991 Feb 12;65(2):130-3 PubMed

Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1918-23 PubMed

Diabetes Metab Res Rev. 2000 May-Jun;16(3):192-201 PubMed

Metabolism. 1990 Oct;39(10):1044-8 PubMed

Am J Hypertens. 1996 May;9(5):484-90 PubMed

Arterioscler Thromb. 1994 Dec;14(12):1885-91 PubMed

Am J Hypertens. 2006 Dec;19(12):1293-9 PubMed

Diabetes. 1997 May;46(5):860-7 PubMed

Diabetes. 1998 Feb;47(2):290-3 PubMed

Metabolism. 1989 Sep;38(9):913-5 PubMed

Stroke. 1998 Jul;29(7):1378-82 PubMed

Atherosclerosis. 2004 Aug;175(2):345-51 PubMed

J Clin Endocrinol Metab. 1998 Nov;83(11):3925-9 PubMed

Am J Cardiol. 2009 Nov 15;104(10):1383-8 PubMed

Thromb Haemost. 1992 Jan 23;67(1):117-20 PubMed

Kidney Int. 2008 Oct;74(7):851-3 PubMed

Thromb Res. 2009;123(3):466-75 PubMed

J Hypertens. 1995 Jun;13(6):659-66 PubMed

Circulation. 1997 Aug 19;96(4):1102-8 PubMed

Curr Atheroscler Rep. 2008 Oct;10(5):386-90 PubMed

Metabolism. 2006 Nov;55(11):1508-15 PubMed

Int J Clin Lab Res. 1996;26(1):1-6 PubMed

Circulation. 1998 Nov 24;98(21):2241-7 PubMed

J Thromb Haemost. 2005 Feb;3(2):280-6 PubMed

Arterioscler Thromb. 1992 Feb;12(2):187-95 PubMed

Exp Clin Endocrinol Diabetes. 2001;109(4):S516-26 PubMed

Lancet. 2001 Dec 15;358(9298):2026-33 PubMed

Circulation. 1996 Aug 1;94(3):273-8 PubMed

Thromb Res. 2002 Jan 1;105(1):25-31 PubMed

Diabetes Care. 2000 Sep;23(9):1395-400 PubMed

Circulation. 2004 Oct 26;110(17):2687-93 PubMed

Diabetes Metab Res Rev. 2008 Feb;24(2):141-7 PubMed

Lancet. 2003 Mar 1;361(9359):777-80 PubMed

Horm Metab Res. 2003 Mar;35(3):178-82 PubMed

Clin Chem. 1996 Apr;42(4):515-23 PubMed

J Thromb Haemost. 2005 Apr;3(4):662-4 PubMed

Circulation. 2004 Mar 23;109(11):1343-8 PubMed

Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):2019-23 PubMed

Circulation. 1997 Sep 2;96(5):1432-7 PubMed

Circulation. 2003 Nov 11;108(19):2312-6 PubMed

Atherosclerosis. 2000 Dec;153(2):483-90 PubMed

Diabetologia. 1985 Jul;28(7):412-9 PubMed

Diabetologia. 1998 Jan;41(1):65-71 PubMed

Int J Obes Relat Metab Disord. 1999 Apr;23(4):336-41 PubMed

Stroke. 1996 Mar;27(3):450-4 PubMed

Circulation. 1997 Nov 4;96(9):2868-76 PubMed

Atherosclerosis. 1994 Apr;106(2):241-53 PubMed

Thromb Haemost. 1988 Dec 22;60(3):491-4 PubMed

Lipids. 2005 Dec;40(12):1215-20 PubMed

Horm Metab Res. 2001 Oct;33(10):602-7 PubMed

Curr Opin Lipidol. 2004 Aug;15(4):433-8 PubMed

Thromb Haemost. 1989 Sep 29;62(2):723-8 PubMed

Vascular Damage and Glycometabolic Control in Older Patients with Type 2 Diabetes